S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

PreludeDx and Learn Look Locate Partner to Demystify DCIS Treatment

Patients facing a ductal carcinoma in situ (DCIS) diagnosis often struggle to navigate complex treatment paths while processing initial clinical results. A new collaboration between diagnostic firm PreludeDx and the education platform Learn Look Locate aims to bridge this information gap with a specialized, patient-centered guide on radiation therapy decisions.

PreludeDx and Learn Look Locate Partner to Demystify DCIS Treatment
Photo: Bio & News

The guide, titled "Do I Need Radiation If I Have DCIS? A Complete, Patient-Centered Guide to Making the Right Decision for You," serves as a roadmap for women evaluating their post-lumpectomy options. It breaks down the nuances of recurrence risk and the function of DCISionRT, a molecular test developed by PreludeDx that estimates a patient’s 10-year risk profile to help tailor treatment plans.

Dr. Barry Rosen, a breast surgeon and senior medical advisor for Learn Look Locate, noted that integrating molecular data into the decision-making process provides a necessary layer of clarity for patients. By offering a structured way to evaluate individual risk, the partners hope to move beyond standard protocols toward more personalized clinical conversations. The resource is currently available online, offering patients a framework to discuss specific diagnostic insights with their care teams.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!